Prosecution Insights
Last updated: August 18, 2026
Application No. 18/813,886

COMPOSITIONS AND METHODS FOR DETECTING BINDING INTERACTIONS UNDER EQUILIBRIUM OR NON-EQUILIBRIUM CONDITIONS

Non-Final OA §112
Filed
Aug 23, 2024
Priority
Aug 24, 2023 — provisional 63/578,624 +1 more
Examiner
GREENE, CAROLYN LEE
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nautilus Subsidiary Inc.
OA Round
5 (Non-Final)
65%
Grant Probability
Moderate
5-6
OA Rounds
1y 4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
133 granted / 205 resolved
+4.9% vs TC avg
Strong +50% interview lift
Without
With
+49.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
39 currently pending
Career history
257
Total Applications
across all art units

Statute-Specific Performance

§101
7.4%
-32.6% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
8.8%
-31.2% vs TC avg
§112
41.7%
+1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 205 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application The Response and the Request for Continued Examination, each filed May 4, 2026, are acknowledged. Claims 1-19, 21-27 and 98-100 were pending. Claims 1-4, 8, 10-11, 13, 17-19, 98-100 and new claims 101-104 are being examined on the merits. Claim 12 remains withdrawn. New claim 105 is newly withdrawn. Claims 14-16 and 27 were withdrawn and are now canceled. Claims 5-7, 9 and 21-26 are canceled. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 4, 2026 has been entered. Response to Arguments Applicant’s arguments filed May 4, 2026 have been fully considered. The following rejections are WITHDRAWN in view of the instant claim amendments: Objection to claim 98 Prior Art rejections Response to arguments regarding prior art rejections The Examiner agrees with Applicant’s arguments as to the differences between the combined teachings of Aksel and Zhu and the instantly claimed method (Remarks, pp. 7-9). The prior art rejections are withdrawn. Election/Restrictions Newly submitted claim 105 is directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the subject matter of independent claim 1 plus its dependent claims and claim 105 are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another and materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case, the apparatus as claimed can be used to practice another and materially different process, e.g., a method of detecting a reaction at each site of a plurality of sites simultaneously (as opposed to only a subset of the plurality of sites). Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 105 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. To preserve a right to petition, the reply to this action must distinctly and specifically point out supposed errors in the restriction requirement. Otherwise, the election shall be treated as a final election without traverse. Traversal must be timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are subsequently added, applicant must indicate which of the subsequently added claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Claim Objections Claim 10 is objected to because of the following informalities: In claim 10, the limitation “bringing the second fluorescent label with the first distance” in ll. 1-2 should be “bringing the second fluorescent label within the first distance”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 8, 10-11, 13, 17-19 and 98-104 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 has been amended to recite, in part, “(b) forming a reaction between a first set of analytes … and affinity reagents … at a first set of sites of the plurality of sites”, the meaning of which is unclear. Specifically, it is unclear if the phrase “forming the reaction” is stating the outcome of practicing the steps recited in (a), or if some additional step(s) must be completed to form the reaction. Further, if additional steps are required, it is not clear if those steps are applied to each site of the plurality of sites or only to each site at the first set of sites. Since the ordinary artisan would not be able to determine the metes and bounds of the claim, it is indefinite. Claims 2-4, 8, 10-11, 13, 17-19 and 98-104 depend directly or indirectly from claim 1, and consequently incorporate the indefiniteness issues of claim 1. Claim 11 recites the limitation “wherein the [first/second] fluorescent label comprises a [first/second] oligonucleotide”, the meaning of which is unclear. That is, while a fluorescent label can be attached to an oligonucleotide, it is not clear how a fluorescent label can comprise an oligonucleotide. Since the ordinary artisan would not be able to determine the metes and bounds of the claim, it is indefinite. Claim 13 depends from claim 11, and consequently incorporates the indefiniteness issues of claim 11. Conclusion Claims 1-4, 8, 10-11, 13, 17-19 and 98-104 are being examined, and are rejected. Claim 10 is objected to. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CAROLYN GREENE whose telephone number is (571)272-3240. The examiner can normally be reached M-Th 7:30-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CAROLYN L GREENE/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Show 5 earlier events
Jun 25, 2025
Response after Non-Final Action
Jul 16, 2025
Non-Final Rejection mailed — §112
Aug 05, 2025
Interview Requested
Oct 13, 2025
Response Filed
Feb 04, 2026
Final Rejection mailed — §112
May 04, 2026
Request for Continued Examination
May 05, 2026
Response after Non-Final Action
Aug 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637712
Fragmentation of DNA
3y 1m to grant Granted May 26, 2026
Patent 12630859
METHOD FOR TRANSCRIPTOME ANALYSIS OF SINGLE CELLS
7y 6m to grant Granted May 19, 2026
Patent 12618113
GENETIC TEST KIT FOR DETECTING THALASSEMIA
2y 4m to grant Granted May 05, 2026
Patent 12612614
STABILIZATION OF RNA
7y 7m to grant Granted Apr 28, 2026
Patent 12590327
COMPOUNDS, COMPOSITIONS, AND METHODS FOR IMPROVING ASSAYS
5y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+49.7%)
3y 3m (~1y 4m remaining)
Median Time to Grant
High
PTA Risk
Based on 205 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month